Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.38 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24914051 | 1.00 | NR1H2 (0.47) | NR1H2ESR2GPR119HRH3PRMT5 | |
| SCHEMBL31013849 | 0.92 | GPR119 (0.45) | NR1H2ESR2GPR119HRH3PDE4B | |
| SCHEMBL31013875 | 0.84 | ESR2 (0.52) | NR1H2ESR2ADORA1 | |
| SCHEMBL31013862 | 0.82 | ESR2 (0.62) | NR1H2ESR2GPR119HRH3PRMT5 | |
| SCHEMBL31014050 | 0.82 | NR1H2 (0.64) | NR1H2ESR2GPR119HRH3PRMT5 | |
| SCHEMBL31014016 | 0.81 | ESR2 (0.49) | NR1H2ESR2ADORA1 | |
| SCHEMBL24914052 | 0.80 | HRH3 (0.41) | NR1H2ESR2GPR119HRH3PRMT5 | |
| SCHEMBL26657625 | 0.80 | F10 (0.41) | NR1H2ESR2GPR119HRH3PRMT5 | |
| SCHEMBL31013899 | 0.79 | GPR119 (0.56) | NR1H2ESR2GPR119HRH3PRMT5 | |
| SCHEMBL30156710 | 0.79 | ESR2 (0.46) | NR1H2ESR2GPR119ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293392-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-09-05 | — | — | US | disclosed |
| CN-117693507-A | Inhibitor compounds | 奈奥芬莱有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023002165-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293392-A1 | INHIBITOR COMPOUNDS | MSH2, PMS2, MSH6 | NR1H2 2027/4885ESR2 568/4885GPR119 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.